Prior to H.I.G., Mr. Zisson spent 13 years making similar investments at Thomas, McNerney & Partners. Previous board seats included Taconic Biosciences (sold to Avista), Arvelle Therapeutics (sold to Angelini) Auspex Pharmaceuticals (public, then sold to Teva), InnoPharma (sold to Pfizer), Quinnova (sold to Amneal), Celator (public, then sold to Jazz), Zogenix (public), Tranzyme (merged with Ocera) and observer roles at PCI Pharma Services (sold to Partners Group) and Coley Pharmaceutical (public, then sold to Pfizer).
Prior to Thomas, McNerney, he spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). During his tenure at H&Q, he led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, he became the firm’s healthcare strategist. He was named twice in The Wall Street Journal All-Star Analysts Survey, including his last year at JPMorgan in which he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and ‘home run’ hitting (#8 across all industries).
Mr. Zisson is the co-chair of the Business Advisory Council of the Children’s Tumor Foundation, on the advisory board for Brown University’s medical school, and is on the Life Sciences Council for Springboard Enterprises, a group that assists women in entrepreneurial roles. He is also a board member for the Greenwich Council of the Boy Scouts of America.
He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.